语言版本

Time of issue:2021-09-02 16:56:33

中文    English
搜索
Search
Homepage
/
About us
All categories
Category brief summary: 新闻资讯
CPHI Barcelona, 2023
CPHI Barcelona, 2023
2023/09/06
CPHI Barcelona, 2023
Time：October 24-26, 2023
Location：Barcelona
Please send email to api@huapont.cn to make an appointment for meeting. We’ll see you there
View More →
Time：October 24-26, 2023
Location：Barcelona
Please send email to api@huapont.cn to make an appointment for meeting. We’ll see you there
CPHI China, 2023
CPHI China, 2023
2023/04/26
CPHI China, 2023
Time：June 19-21, 2023
Location：Shanghai, China
Please send email to api@huapont.cn to make an appointment for meeting. We’ll see you there
View More →
Time：June 19-21, 2023
Location：Shanghai, China
Please send email to api@huapont.cn to make an appointment for meeting. We’ll see you there
CPHI Japan, 2023
CPHI Japan, 2023
2023/04/26
CPHI Japan, 2023
Time：April 19-21, 2023
Location：Japan
Please send email to api@huapont.cn to make an appointment for meeting. We’ll see you there
View More →
Time：April 19-21, 2023
Location：Japan
Please send email to api@huapont.cn to make an appointment for meeting. We’ll see you there
Huapont Would Attend DCAT, March 20-23, 2023
Huapont Would Attend DCAT, March 20-23, 2023
2023/02/21
Huapont Would Attend DCAT, March 20-23, 2023
DCAT Week
View More →
DCAT Week
Huapont is awarded with CEP certificate of Tretinoin
2022/09
Huapont is awarded with CEP certificate of Tretinoin
Huapont Shengchem obtained Ruxolitinib Phosphate WC certificate
Huapont Shengchem obtained Ruxolitinib Phosphate WC certificate
2022/05/27
Huapont Shengchem obtained Ruxolitinib Phosphate WC certificate
Huapont Shengchem is one of leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Ruxolitinib Phosphate (CAS Number: 1092939-17-7) API. DMF (No. 029480）has been submitted to US FDA and it is available for reference. In early time of this month, Huapont shengchem GMP management system has been inspected by Chongqing Municiple Drug Administration. Huapont Shengchem passed the inspection and obtained Ruxolitinib Phosphate WC certificate (Written confirmation for active substances exported to EU). Label of JAKAFI® (Manufactured by Incyte Corporation) showes Ruxolitinib Phosphate tablet is a kinase inhibitor indicated for treatment of: (1) intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis in adults; (2) polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea; (3)steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older; (4) chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. A topical use drug product with new preparation (cream) was newly approved by US FDA in 2021.
View More →
Huapont Shengchem is one of leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Ruxolitinib Phosphate (CAS Number: 1092939-17-7) API. DMF (No. 029480）has been submitted to US FDA and it is available for reference. In early time of this month, Huapont shengchem GMP management system has been inspected by Chongqing Municiple Drug Administration. Huapont Shengchem passed the inspection and obtained Ruxolitinib Phosphate WC certificate (Written confirmation for active substances exported to EU). Label of JAKAFI® (Manufactured by Incyte Corporation) showes Ruxolitinib Phosphate tablet is a kinase inhibitor indicated for treatment of: (1) intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis in adults; (2) polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea; (3)steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older; (4) chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. A topical use drug product with new preparation (cream) was newly approved by US FDA in 2021.
Huapont was awarded <Certificate of Intellectual Property Management System>
Huapont was awarded <Certificate of Intellectual Property Management System>
2021/12/22
Huapont was awarded <Certificate of Intellectual Property Management System>
　　On March 1, 2013, was published. It helped raising awareness of intellectual property right, innovation and furtherly enhancing innovation capacity. Recently, intellectual property management system of Huapont was inspected and approved by Zhongbiaotong International Certification (Shenzhen) Co., Ltd. Huapont was awarded .  
View More →
　　On March 1, 2013, was published. It helped raising awareness of intellectual property right, innovation and furtherly enhancing innovation capacity. Recently, intellectual property management system of Huapont was inspected and approved by Zhongbiaotong International Certification (Shenzhen) Co., Ltd. Huapont was awarded .  
Huapont Life Sciences ranked top 100 private enterprises in Chongqing
Huapont Life Sciences ranked top 100 private enterprises in Chongqing
2021/10/28
Huapont Life Sciences ranked top 100 private enterprises in Chongqing
On October 9,2021, “2021 Chongqing Top 100 Private Enterprises Summit” was hold in Chongqing, hosted by Chongqing Federation of Industry and Commerce,
View More →
On October 9,2021, “2021 Chongqing Top 100 Private Enterprises Summit” was hold in Chongqing, hosted by Chongqing Federation of Industry and Commerce,
Isotretinoin process 2 obtained CEP certification (No. 2018-219).
2019/01
Isotretinoin process 2 obtained CEP certification (No. 2018-219).
Moxifloxacin Hydrochloride, Olopatadine Hydrochloride and Linezolid obtained the GMP certificate issued by China-NMPA (National Medical Products Administration).
2019/02
Moxifloxacin Hydrochloride, Olopatadine Hydrochloride and Linezolid obtained the GMP certificate issued by China-NMPA (National Medical Products Administration).
Huapont Pharm. has awarded with “2020 Benchmark Intelligent Manufacturer of Chongqing”
Huapont Pharm. has awarded with “2020 Benchmark Intelligent Manufacturer of Chongqing”
2020/09/15
Huapont Pharm. has awarded with “2020 Benchmark Intelligent Manufacturer of Chongqing”
On September 15th, ceremony of “2020 Benchmark Intelligent Manufacturer of Chongqing” was held successfully at The Third Industrial and Intelligent Manufacturing Summit Forum of Smart China Expo Online 2020.
View More →
On September 15th, ceremony of “2020 Benchmark Intelligent Manufacturer of Chongqing” was held successfully at The Third Industrial and Intelligent Manufacturing Summit Forum of Smart China Expo Online 2020.
TDMF for Moxifloxacin HCl is approved by Taiwan FDA
2020/04
TDMF for Moxifloxacin HCl is approved by Taiwan FDA
US-DMF of Bendamustine HCl was approved by FDA (allied dosage was approved).
2020/04
US-DMF of Bendamustine HCl was approved by FDA (allied dosage was approved).
Moxifloxacin HCl obtained the GMP certificate issued by PMDA.
2020/02
Moxifloxacin HCl obtained the GMP certificate issued by PMDA.
Roflumilast, Calcipotriol Monohydrate, Alitretinoin, bepotastine besilate, Bexarotene, Bendamustine Hydrochloride and Bendamustine Hydrochloirde Monohydrate obtained W/C (Written Confirmation).
2020/01
Roflumilast, Calcipotriol Monohydrate, Alitretinoin, bepotastine besilate, Bexarotene, Bendamustine Hydrochloride and Bendamustine Hydrochloirde Monohydrate obtained W/C (Written Confirmation).
Tretinoin, Tazarotene, Calcipotriol, Acrivastine, Levocetirizine Hydrochloride, Dapsone, Naftifine Hydrochloride, Olopatadine Hydrochloride and Moxifloxacin Hydrochloride obtained W/C (Written Confirmation).
2019/07
Tretinoin, Tazarotene, Calcipotriol, Acrivastine, Levocetirizine Hydrochloride, Dapsone, Naftifine Hydrochloride, Olopatadine Hydrochloride and Moxifloxacin Hydrochloride obtained W/C (Written Confirmation).
Isotretinoin and Acitretin obtained renewal W/C (Written Confirmation).
2019/04
Isotretinoin and Acitretin obtained renewal W/C (Written Confirmation).
Alitretinoin obtained the GMP certificate from South Korean FDA.
2019/01
Alitretinoin obtained the GMP certificate from South Korean FDA.
The manufacturing site is informed approved by the US-FDA inspection.
2018/09
The manufacturing site is informed approved by the US-FDA inspection.
DMF of Isotretinoin is submitted to Saudi FDA.
2017/11
DMF of Isotretinoin is submitted to Saudi FDA.
Previous page
1
2

RELATED WEBSITES

友情链接

Time of issue:2020-07-27 00:00:00

Chongqing Huapont Pharmaceutical Co., Ltd

Huapont Life Sciences Co., Ltd
Online customer service
微信号:123123123
手机扫一扫联系我们
手机扫一扫加入我们
img
Customer service hotline
+86-023-67886928 +86-023-67886928
Service time:
8:30 - 17:30
Customer service group:
在线客服

地址版权

Time of issue:2019-05-10 00:00:00

© 2021 Chongqing Huapont Pharmaceutical Co., Ltd. All Rights Reserved.  渝ICP备2021007919号  1渝公网安备50011702500758号  Powered by：www.300.cn

地址版权手机

Time of issue:2019-05-10 00:00:00

© 2021 Chongqing Huapont Pharmaceutical Co., Ltd.

渝ICP备2021007919号  Powered by：www.300.cn

1渝公网安备50011702500758号